ABBV-383, a BCMA-CD3 bispecific antibody, in relapsed/refractory multiple myeloma: a multicenter, phase 1b dose optimization study with step-up dosing

被引：0

作者：

Baljevic, Muhamed ^{[1
]}

Magen, Hila ^{[2
,3
]}

Searle, Emma ^{[4
,5
]}

Jin, Ziyi ^{[6
]}

Strange, Elise ^{[6
]}

Svensson, Anders ^{[6
]}

Kumar, Shaji ^{[7
]}

机构：

[1] Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, Nashville, TN USA

[2] Chaim Sheba Med Ctr, Ramat Gan, Israel

[3] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel

[4] Christie Hosp NHS Fdn Trust, Manchester, England

[5] Univ Manchester, Manchester, England

[6] AbbVie Inc, N Chicago, IL USA

[7] Mayo Clin, Rochester, MN USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-231

引用

页码：S162 / S163

页数：2

共 50 条

[1] Efficacy and Safety of ABBV-383, a BCMA Bispecific Antibody, in Black Patients With Relapsed/Refractory Multiple Myeloma: A Subgroup Analysis of a Phase 1 Trial
D'Souza, Anita
Rodriguez-Valdes, Cesar
Kumar, Shaji
Chung, Alfred
Tuchman, Sascha
Safah, Hana
Weisel, Katja
Teipel, Raphael
Korde, Neha
Vij, Ravi
Bueno, Orlando
Rosenberg, Tanya
Pothacamury, Rajvineeth
Polepally, Akshanth
Ahsan, Aarif
Lee, Shane
Jin, Ziyi
Spence, Shelli
Talati, Chetasi
McKay, John
Voorhees, Peter M.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S48 - S48
[2] A Phase 1 First-in-Human Study of Abbv-383, a BCMA x CD3 Bispecific T-Cell-Redirecting Antibody, As Monotherapy in Patients with Relapsed/Refractory Multiple Myeloma
Voorhees, Peter M.
D'Souza, Anita
Weisel, Katja
Hurd, David Duane
Teipel, Raphael
Chung, Alfred
Rodriguez, Cesar
Tuchman, Sascha A.
Korde, Neha
Safah, Hana
Bueno, Orlando F.
Pumford, Neil
Rosenberg, Tanya S.
Pothacamury, Rajvineeth Kumar
Ross, Jeremy A.
Polepally, Akshanth R.
Lee, Shane
Jin, Ziyi
Talati, Chetasi
Vij, Ravi
Kumar, Shaji K.
BLOOD, 2022, 140 : 4401 - 4404
[3] Efficacy, safety, and determination of RP2D of ABBV-383, a BCMA bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM).
Valdes, Cesar Rodriguez
Voorhees, Peter M.
D'Souza, Anita
Chung, Alfred
Tuchman, Sascha
Safah, Hana
Mckay, John T.
Weisel, Katja C.
Teipel, Raphael
Korde, Neha
Vij, Ravi
Bueno, Orlando Felix
Rosenberg, Tanya
Pothacamury, Rajvineeth Kumar
Polepally, Akshanth
Ahsan, Aarif
Li , Xin
Jin, Ziyi
Talati, Chetasi
Kumar, Shaji
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[4] Updated results of a phase 1, first-in-human study of ABBV-383, a BCMA x CD3 bispecific T-cell redirecting antibody, in patients with relapsed/refractory multiple myeloma
Voorhees, Peter
Shah, Nina
D'Souza, Anita
Rodriguez, Cesar
Weisel, Katja
Teipel, Raphael
Hurd, David
Bueno, Orlando
Pumford, Neil
Rosenberg, Tanya
Pothacamury, Rajvineeth Kumar
Ross, Jeremy
Polepally, Akshanth
Lee, Shane
Jin, Ziyi
Talati, Chetasi
Kumar, Shaji
Vij, Ravi
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S34 - S34
[5] Correlative biomarker analyses for optimal therapeutic dose determination of ABBV-383, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM).
Ahsan, Aarif
Mantis, Christine
Luo, Xizhi
Zhang, Catherine C.
Valdes, Cesar Rodriguez
Voorhees, Peter M.
D'Souza, Anita
Chung, Alfred
Tuchman, Sascha
Safah, Hana
Mckay, John T.
Weisel, Katja C.
Teipel, Raphael
Korde, Neha
Vij, Ravi
Kumar, Shaji
Bueno, Orlando Felix
Pothacamury, Rajvineeth Kumar
Talati, Chetasi
Ross, Jeremy A.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[6] Updated Safety and Efficacy Results of Abbv-383, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in a First-in-Human Phase 1 Study in Patients with Relapsed/Refractory Multiple Myeloma
Vij, Ravi
Kumar, Shaji Kunnathu
D'Souza, Anita
Mckay, John T.
Voorhees, Peter M.
Chung, Alfred
Tuchman, Sascha Alexander
Korde, Neha
Weisel, Katja
Teipel, Raphael
Bueno, Orlando
Feng, Zhongling
Rosenberg, Tanya S.
Pothacamury, Rajvineeth Kumar
Polepally, Akshanth R.
Lee, Shane
Jin, Ziyi
Ross, Jeremy A.
Ahsan, Aarif
Talati, Chetasi
Rodriguez, Cesar
BLOOD, 2023, 142
[7] Pharmacokinetics and Immunogenicity of Abbv-383, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific T-Cell-Redirecting Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Polepally, Akshanth R.
Biesdorf, Carla
Uddin, Muhammad Erfan
Boehm, Nils
Ross, Jeremy A.
Kumar, Shaji Kunnathu
Voorhees, Peter M.
D'Souza, Anita
Weisel, Katja
Bueno, Orlando
Talati, Chetasi
Menon, Rajeev M.
BLOOD, 2023, 142
[8] POPULATION PHARM ACOKINETICS (POPPK) OF ABBV-383, A B-CELL MATURATION ANTIGEN (BCMA) x CD3 BISPECIFIC T-CELL-REDIRECTING ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
Polepally, A.
Badillo, J.
Rinas, M.
Ahsan, A.
Bueno, O.
Talati, C.
Menon, R.
Engelhardt, B.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S69 - S69
[9] A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen x CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma
D'Souza, Anita
Shah, Nina
Rodriguez, Cesar
Voorhees, Peter M.
Weisel, Katja
Bueno, Orlando F.
Pothacamury, Rajvineeth K.
Freise, Kevin J.
Yue, Susan
Ross, Jeremy A.
Polepally, Akshanth R.
Talati, Chetasi
Lee, Shane
Jin, Ziyi
Buelow, Ben
Vij, Ravi
Kumar, Shaji
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (31) : 3576 - +
[10] CERVINO: A Phase 3, Multicenter, Randomized, Open-Label Study of ABBV-383 Compared With Standard Available Therapies in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
Costa, Luciano
Mateos Manteca, Maria-Victoria
Voorhees, Peter M.
Iida, Shinsuke
Cole, Craig
Quach, Hang
Pothacamury, Rajvineeth
Bueno, Orlando
Lee, Shane
Rosenberg, Tanya
Talati, Chetasi
Kumar, Shaji
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S47 - S48

← 1 2 3 4 5 →